Log in

9606 Duality Biotherapeutics, Inc. HKEX · China

Duality Biotherapeutics (9606) news

Duality Biotherapeutics, Inc. is a public biotech or pharmaceutical company listed on HKEX under the ticker 9606, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Duality Biotherapeutics news

We have not published a story on Duality Biotherapeutics yet. When there is news, it will appear here.

Questions about Duality Biotherapeutics

What is the ticker symbol of Duality Biotherapeutics?

Duality Biotherapeutics, Inc. trades under the ticker 9606 on HKEX.

Where is Duality Biotherapeutics listed?

Duality Biotherapeutics, Inc. is listed on HKEX. Our directory also records these other listings: LS:A414LZ; LSX:A414LZ.

Which country or territory is Duality Biotherapeutics listed under?

Our directory records Duality Biotherapeutics, Inc. under China.

What does Duality Biotherapeutics do?

Our directory classifies Duality Biotherapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Duality Biotherapeutics?

The ISIN recorded for Duality Biotherapeutics, Inc. is KYG2929M1087.

Does aibio.space cover Duality Biotherapeutics?

aibio.space lists Duality Biotherapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Duality Biotherapeutics?

Companies in our directory listed in the same country and business area as Duality Biotherapeutics: Jiangxi Institute of Biological Products, Boji Medical Technology Co., HJ Science Co., Jiangsu gdk Biotechnology Co., Shaanxi Micot Pharmaceutical Technology Co., Guangzhou LBP Medicine Science & Technology Co..

Investor discussion: Duality Biotherapeutics

Members talk about Duality Biotherapeutics (9606). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Duality Biotherapeutics, newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section. Source

  2. Financings

    Share or debt issue: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section. Source

  3. Financings

    Share or debt issue: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section. Source

  4. Financings

    Share or debt issue: ACCEPTANCE BY THE SHANGHAI STOCK EXCHANGE OF APPLICATION MATERIALS FOR THE RMB SHARE ISSUE. Source

  5. Financings

    Share or debt issue: (1) PROPOSED GRANTING OF GENERAL MANDATE TO REPURCHASE SHARES; (2) PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES (INCLUDING SALE OR TRANSFER OF TREASURY SHARES); (3) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (4) PROPOSED RE-APPOINTMENT OF AUDITORS; AND (5) NOTICE OF ANNUAL GENERAL MEETING. Source

  6. Financings

    Share or debt issue: (1) PROPOSED ISSUE OF RMB SHARES UNDER SPECIFIC MANDATE AND LISTING ON THE SCI-TECH BOARD AND OTHER ANCILLARY RESOLUTION; (2) PROPOSED AMENDMENTS TO THE ARTICLES ANCILLARY TO THE PROPOSED ISSUE; AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING. Source

  7. Financings

    Share or debt issue: (1) PROPOSED ISSUE OF RMB SHARES UNDER SPECIFIC MANDATE AND LISTING ON THE SCI-TECH BOARD; AND (2) PROPOSED AMENDMENTS TO THE ARTICLES ANCILLARY TO THE PROPOSED ISSUE. Source

  8. Financings

    Share or debt issue: (1) PROPOSED GRANTING OF GENERAL MANDATE TO REPURCHASE SHARES; (2) PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES (INCLUDING SALE OR TRANSFER OF TREASURY SHARES); (3) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (4) PROPOSED RE-APPOINTMENT OF AUDITORS; AND (5) NOTICE OF ANNUAL GENERAL MEETING. Source

  9. Financings

    Share or debt issue: GLOBAL OFFERING. Source

Press releases

Headlines of Duality Biotherapeutics's own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    INSIDE INFORMATION - UPDATE ON THE DYNASTY-BREAST02 GLOBAL PHASE 3 CLINICAL TRIAL OF TRASTUZUMAB PAMIRTECAN

  2. HKEXnews

    An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

  3. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

  4. HKEXnews

    INSIDE INFORMATION - GLOBAL RESEARCH AND DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT WITH GENENTECH, INC. TO DEVELOP NEXT-GENERATION ADCS BUILT ON THE COMPANY'S DUPAC NOVEL-PAYLOAD PLATFORM

  5. HKEXnews

    (1) CHANGE OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT; (2) WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES; AND (3) CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

  6. HKEXnews

    GRANT OF RESTRICTED SHARE UNITS UNDER THE 2025 SHARE SCHEME

  7. HKEXnews

    POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2026

  8. HKEXnews

    ACCEPTANCE BY THE SHANGHAI STOCK EXCHANGE OF APPLICATION MATERIALS FOR THE RMB SHARE ISSUE

  9. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ACCEPTANCE ON COUNSELLING FROM SHANGHAI SECURITIES REGULATORY BUREAU REGARDING PROPOSED LISTING OF RMB SHARES ON SCI-TECH BOARD

  10. HKEXnews

    NOTICE OF ANNUAL GENERAL MEETING

  11. HKEXnews

    (1) PROPOSED GRANTING OF GENERAL MANDATE TO REPURCHASE SHARES; (2) PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES (INCLUDING SALE OR TRANSFER OF TREASURY SHARES); (3) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (4) PROPOSED RE-APPOINTMENT OF AUDITORS; AND (5) NOTICE OF ANNUAL GENERAL MEETING

  12. HKEXnews

    VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE PLAN UNDER THE REPURCHASE MANDATE AND PROPOSED INCREASE IN SHAREHOLDING BY CHAIRMAN OF THE BOARD

  13. HKEXnews

    INSIDE INFORMATION NOTICE OF EXERCISE OF THE DB-1311/BNT324 COST & PROFIT/LOSS SHARING OPTION

  14. HKEXnews

    POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON APRIL 29, 2026

  15. HKEXnews

    NOTICE OF THE EXTRAORDINARY GENERAL MEETING

  16. HKEXnews

    (1) PROPOSED ISSUE OF RMB SHARES UNDER SPECIFIC MANDATE AND LISTING ON THE SCI-TECH BOARD AND OTHER ANCILLARY RESOLUTION; (2) PROPOSED AMENDMENTS TO THE ARTICLES ANCILLARY TO THE PROPOSED ISSUE; AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING

  17. HKEXnews

    (1) PROPOSED ISSUE OF RMB SHARES UNDER SPECIFIC MANDATE AND LISTING ON THE SCI-TECH BOARD; AND (2) PROPOSED AMENDMENTS TO THE ARTICLES ANCILLARY TO THE PROPOSED ISSUE

  18. HKEXnews

    INSIDE INFORMATION BIOLOGICS LICENSE APPLICATION FOR DB-1303/BNT323 FOR UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER IN ADULTS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

  19. HKEXnews

    BOOK CLOSURE PERIOD FOR THE EXTRAORDINARY GENERAL MEETING

  20. HKEXnews

    ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:9606 on TradingView.

Listing details

Duality Biotherapeutics, Inc. is a public biotech or pharmaceutical company listed on HKEX under the ticker 9606, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Duality Biotherapeutics, Inc.
Ticker
9606
Listing
HKEX
Country or territory
China
Business scope
Biotechnology
ISIN
KYG2929M1087
Other listed symbols
LS:A414LZ; LSX:A414LZ
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.